Methods
To identify potential clinically significant life-threatening DDIs, this study used the U.S. Food and Drug Administration (FDA) prescribing table of LPV/RTV enlisted contraindicated medications 9. Likely, potential clinically significant life-threatening DDIs were also identified from the lists of contraindicated drugs of LPV/RTV as provided by the Liverpool COVID-19 drug interaction resource10. The interacting contraindicated drugs were putatively paired with LPV/RTV called severe DDI pairs predicted to cause life-threatening ADRs.
The severe DDI pairs identified from the FDA and Liverpool COVID-19 interaction resources were then analyzed using a Venn diagram showing the unique or overlapping drug pairs between these two well recognized evidence-based international DDI resources.